Posts by Sandra Ansanay-Alex
Raphaël Conz is the New Head of Department for Economic Promotion and Innovation in the canton of Vaud
Raphaël Conz is also BioAlps’ vice-president. For many years, he has worked to promote the attractiveness and the reputation of the Swiss Health Valley The State Council of the Canton of Vaud has appointed Raphaël Conz Head of the Department for the Promotion of the Economy and Innovation. He will fill his new position…
Read MoreMedistri invests CHF 8 million in Domdidier
The largest independent sterilisation company in Europe invests to expand its plant in Domdidier, in the canton of Fribourg. On 29 November 2022, Medistri has been granted its building permit for the construction of an extension and realization of new facilities. This expansion will allow Medistri SA to develop and increase its production at…
Read MoreOculis Announces US public listing on Nasdaq
A Swiss Health Valley success story! Oculis goes public. Oculis Holding AG (“Oculis”), based at EPFL Innovation Park in Lausanne, is a global biopharmaceutical company purposefully driven to save sight and improve eye care. On 3 March 2023, it announced its listing on Nasdaq after successfully closing the business combination between European Biotech Acquisition…
Read MoreComphya receives approval for first pilot clinical trial in Australia
A swissmade neuromodulator to treat erectile dysfunction starts clinical trials in Australia Comphya SA, developer of the first neuromodulator to treat erectile dysfunction (ED), announced today that Australian regulatory authorities (Human Research Ethics Committees (HREC) and Therapeutic Goods Administration (TGA)) have approved the pilot clinical trial for CaverSTIM in patients undergoing prostatectomy. This will…
Read MoreFluoSphera Secures a Pre-Seed Investment of $ 1M
The US accelerator IndieBio New York which is part of SOSV, Swiss-based Mountain Labs, and EFI Lake Geneva Ventures participated in this round along with private business angels. Gregory Segala, CEO and co-founder of FluoSphera SA: “We express our deep gratitude to our investors who believe in the potential of our powerful in vitro…
Read MoreLunaphore and CRO Sirona Dx collaborate to expand COMET™ offerings to US-based biotech and biopharma customers
Sirona Dx will become the first US-based Contract Research Organization (CRO) to offer Lunaphore’s flagship COMET™ spatial biology platform as a service. Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Sirona Dx, a leader in multi-omics, single-cell analytical services, today announced a strategic collaboration in which Sirona Dx will become…
Read MoreLeenaards Foundation 2023 Science Prizes
Leenaards Foundation announces three winners of the 2023 Science Prizes. CHF 1.5 million are awarded to support biomedical research in the Swiss Health Valley The Leenaards Foundation will hand out its annual Science Prize, together with over CHF 1.5 million in award money, to three research groups in the Lake Geneva region at a…
Read MoreObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
In financial trouble, the Geneva-based femtech company had to lay off its employees and reorganize its management Obseva, in trouble since it admitted at the end of July that it was unable to complete the registration process for its main product in development, presented on a program to resize its management bodies in particular,…
Read MoreTerapet raises CHF 2,3 million
The Swiss MedTech company is developing next generation imaging technology, and closed a Pre-Series A investment round. This funding supports the commercialization of Terapet’s first product, Qualγscan and the development of new nuclear imaging products. The funding round was co-led by EFI Lake Geneva Ventures and Nina Capital with support of all the existing…
Read MoremimiX Biotherapeutics and PreComb join forces to fight cancer
The two companies are partnering to accelerate the process of personalized cancer drug profiling leveraging the potential of both company’s proprietary technologies. PreComb is pioneering personalized cancer profiling with their proprietary 3DTwin® technology. By using mimiX’s Sound-Induced Morphogenesis (SIM) technology to make efficient use of patient’s tumor cells and accelerate in vitro tissue production, PreComb…
Read More